1st patient dosed in Phase 2 trial of Parkinson’s therapy VTX3232
The first patient with early Parkinson’s disease has been dosed in Ventyx Biosciences‘ Phase 2a clinical trial of Parkinson’s therapy VTX3232, an oral medication designed to reduce inflammation by blocking the activity of the NLRP3